Overview
- Peptide (C)GKERETNEQRQKVE, corresponding to amino acid residues 336-349 of mouse LAT3 (SLC43A1) (Accession Q8BSM7). 4th extracellular loop.
- Rat and mouse lung lysates; human chronic myelogenous leukemia K562 and prostate carcinoma LN-CaP cell lysates (1:200-1:2000).
Western blot analysis of rat lung (lanes 1 and 3) and mouse lung (lanes 2 and 4) lysates:1, 2. Anti-LAT3/SLC43A1 (extracellular) Antibody (#ANT-193), (1:400).
3, 4. Anti-LAT3 (SLC43A1) (extracellular) Antibody, preincubated with LAT3/SLC43A1 (extracellular) Blocking Peptide (#BLP-NT193).
LAT3, (L-type amino acid transporter 3) is an amino acid transporter that belongs to the system L family of membrane transporters.
The system L transporter family consists of various transporter subtypes with different characteristics in substrate selectivity and transport properties. It is characterized by a Na+ independent transport and its inhibition by 2-aminobicyclo heptane-2-carboxylicacid (BCH).
System L transporters are a major route to provide cells with branched-chain and aromatic amino acids. Transporters that belong to this family are present in the basolateral membrane of epithelial cells and play important roles in the absorption of amino acids through the epithelial cells of the small intestine and renal proximal tubules. They are essential in the permeation of amino acids through the blood–tissue barriers such as blood brain barrier and placenta barrier1.
LAT3 consists of seven transmembrane domains with a relatively long extracellular loop with predicted N-linked glycosylation sites between transmembrane domains 1 and 2 and a long intracellular loop with several putative phosphorylation sites between transmembrane domains 6 and 72.
LAT3 was shown to be up-regulated in prostate cancer and responsible for the increased uptake of leucine into the tumor cells. Hence, it is an appealing target for cancer therapy3.
